GlycoMimetics, Inc.
9780 Medical Center Drive
Rockville
Maryland
20850
United States
292 articles about GlycoMimetics, Inc.
-
GlycoMimetics, Inc. To Present At 18th Annual BIO CEO & Investor Conference
2/2/2016
-
GlycoMimetics, Inc. Presents Preclinical Data At American Society of Hematology Annual Meeting Showing GMI-1359 Enhances Efficacy Of Chemotherapy In FLT-3 AML Model
12/7/2015
-
GlycoMimetics, Inc. Presents At American Society of Hematology Meeting First-In-Human Data Showing Favorable Safety, Metabolic And Biomarker Profiles For GMI-1271
12/7/2015
-
GlycoMimetics, Inc. Poster Shows GMI-1271 Reverses Drug Resistance In Multiple Myeloma Models
12/7/2015
-
GlycoMimetics, Inc. Highlights Preclinical Data In Oral Presentation At American Society of Hematology Meeting Demonstrating Impact Of GMI-1271 On T Memory Stem Cells
12/7/2015
-
GlycoMimetics, Inc. To Present At Two Investor Conferences In November
11/13/2015
-
GlycoMimetics, Inc. Reports Third Quarter 2015 Results
11/12/2015
-
GlycoMimetics, Inc. Announces Initiation Of First Clinical Trial Evaluating Subcutaneous Administration Of Rivipansel
10/29/2015
-
GlycoMimetics, Inc. Announces Issuance Of U.S. Composition Of Matter Patent For Drug Candidate GMI-1271
9/1/2015
-
GlycoMimetics, Inc. To Present At The Canaccord Genuity Growth Conference
8/10/2015
-
GlycoMimetics, Inc. Reports Second Quarter 2015 Results
8/7/2015
-
GlycoMimetics, Inc. To Receive $20 Million Payment From Pfizer Following Initiation Of Phase III Trial With Rivipansel
6/24/2015
-
GlycoMimetics, Inc. To Present At The Jefferies and Co. 2015 Healthcare Conference
5/28/2015
-
GlycoMimetics, Inc. Initiates Phase I/II Clinical Trial Of GMI-1271 As Potential Treatment For Acute Myeloid Leukemia In Combination With Chemotherapy
5/19/2015
-
GlycoMimetics, Inc. Initiates Phase I/II Clinical Trial Of GMI-1271 As Potential Treatment For Acute Myeloid Leukemia In Combination With Chemotherapy
5/19/2015
-
FDA Grants Orphan Drug Designation To GlycoMimetics, Inc.’ GMI-1271 For Treatment Of Acute Myleogenous Leukemia (AML)
5/14/2015
-
GlycoMimetics, Inc. Reports First Quarter 2015 Results
5/6/2015
-
GlycoMimetics, Inc. Provides Update On Pfizer’s Plans To Initiate Phase 3 Trial With Rivipansel In Mid-2015
4/7/2015
-
GlycoMimetics, Inc. To Present First Preclinical Data On E-Selectin-CXCR4 Dual Antagonist For Cancer Indications At American Association for Cancer Research Annual Meeting 2015
3/19/2015
-
GlycoMimetics, Inc. Reports Fourth Quarter And Year-End 2014 Results
3/17/2015